News

• Where Is the Future of Innovative Drugs? As AI Moves Deeper In, the Industry Stands at a Critical Crossroads Aug 03, 2026 at 13:56
• The Biotech Recovery Is Here—But It’s “Selective.” Is Your Supply Chain Ready? Jul 29, 2026 at 09:26
• The Cycle Turns: Why R&D Leaders Are Revisiting Their Custom Synthesis Supply Chain Jul 27, 2026 at 14:34
• New GLP-1 Players Emerge + AI Drug Discovery Accelerates—How Custom Synthesis Meets the Dual Surge in Demand Jul 21, 2026 at 10:59
• After AI Accelerates Target Discovery—How Custom Synthesis Fills the Compound Gap for Target Validation Jul 17, 2026 at 16:02
• GLP‑1 Clinical Breakthroughs Drive Demand for Heterocyclic Intermediates – Beixinke Chem’s In‑Stock Solutions Jul 15, 2026 at 17:52
• ADC Next Generation: How Custom Synthesis of Linkers, Payloads, and Heterocyclic Scaffolds Is Powering the Antibody-Drug Conjugate Revolution Jul 07, 2026 at 14:43
• PROTAC Era Has Arrived: How Custom Synthesis Bridges the Gap from Molecular Design to Clinical Supply Jul 01, 2026 at 18:25
• The Hidden Bottleneck in GLP-1 Drug Development: Why Custom Synthesis is the New Competitive Edge Jun 26, 2026 at 19:34
• CDC42 Inhibition Synergies with Immune Checkpoint Inhibitors: Latest Research Highlights Jun 24, 2026 at 18:55
• Beixinke Chemical Achieves 99.89% Purity for Cdc42 Inhibitor ML 141, Enabling More Reproducible Research Jun 22, 2026 at 20:06
• We Are Here: From a Quiet Lab in Shanghai Jun 19, 2026 at 20:37